Medical Technology: NY Valves Day 1: LAAC & TAVR durability

Research evidence excerpt

Medical Technology: NY Valves Day 1: LAAC & TAVR durability

Accessible version

Medical Technology

NY Valves Day 1: LAAC & TAVR durability

Industry Overview

Day 1 at NY Valves 24 June 2026

We are attending NY Valves in NYC, where day 1 focused on LAAC and TAVR late- Equity

breakers. Docs were split on CHAMPION but generally agreed it broadens LAAC United States

optionality and patient discussions, while TAVR debate centered on durability as Medical Technology

treatment moves younger. Partner 3 7-year reintervention remained low, while real- Travis Steed

world Evolut data looked modestly better than MDT’s pivotal low-risk signal, though Research Analyst

docs still want longer-term durability follow-up. BofAS+1 404 607 3251

travis.steed@bofa.com

Docs mixed on CHAMPION, helps patient discussions Stephanie Elghazi

Docs were mixed on how much CHAMPION should change practice, with panelists ResearchBofAS Analyst

agreeing it was controversial and that there is “something for everyone” in the results. +1 646 855 4568 stephanie.elghazi@bofa.com

One panelist said CHAMPION gives docs a better understanding of NOACs vs LAAC,

Aidan Lahey

rather than relying on assumptions that one therapy is as good as the other or that Research Analyst

patients will not bleed. They also said the ~90% NOAC compliance rate is important for BofAS

+1 646 855 2590

patient discussions, because it shows patients need to be compliant to get good aidan.lahey@bofa.com

outcomes. Seeing event rates in each arm helps give concrete framing on pros/cons for Gracia Mahoney

patients on risk, medication access, compliance, and willingness to stay on lifelong Research Analyst BofAS

therapy. Another panelist said CHAMPION could still be a major change because bleeding +1 646 855 1136